Clinical trials: SARS Pneumonia
- Condition SARS Pneumonia
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Covid19
Early Detection of COVID-19 Using Breath Analysis
EARLY DETECTION OF COVID-19 USING BREATH ANALYSIS- FIRST CROSS-SECTIONAL STUDY
- Trial name
- COVID-19 (NCT04602884)
- Testing
- Breath biopsy sampling using the ReCIVA Breath Sampler
- Where
- Israel
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Scentech Medical Technologies Ltd
Vaccine Response Impaired, Vaccine Adverse Reaction
Vaccine Observation to Include All Communities for Equitable Science
VOICES is a longitudinal, prospective, observational study that will enroll up to 10,000 subjects of diverse racial backgrounds being administered an emergency use authorized COVID-19 vaccine, for collection and analysis of stool…
- Trial name
- VOICES (NCT04770649)
- Testing
- COVID-19 vaccine
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Persephone Biosciences
COVID-19
Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada
This study is a phase I /II adaptive clinical trial to evaluate the safety, tolerability and the Immunogenicity of Ad5-nCoV in healthy adults from 18 to <55 and 65 to <85 years of age，with the randomized, observer-blind…
- Trial name
- NCT04398147
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- Where
- Canada
- Volunteers
- 696 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
COVID-19
Clinical Trial of Safety and Immunogenicity of Recombinant SARS-CoV-2 S-Trimer Vaccine (CHO Cells) as Booster Vaccination in Populations Aged 18 to 59 Years
Increased immune escape of emerging SARS-CoV-2 variants and waning neutralizing antibody levels over time indicate the importance of COVID-19 vaccine booster dose.
- Trial name
- NCT05716347
- Testing
- the recombinant SARS-CoV-2 S-Trimer vaccine/inactivated SARS-CoV-2 vaccine
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Binhui Biopharmaceutical Co., Ltd.
SARS-CoV-2 Infection
Evaluate the Efficacy and Safety of Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Covid-19
A Phase II/III Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Individuals Infected with SARS-CoV-2
- Trial name
- NCT05633433
- Testing
- Azvudine
- Where
- 10 sites in Malaysia, Philippines
- Volunteers
- 1,550 people, healthy volunteers welcome
- Sponsor
- Shanghai Henlius Biotech
COVID-19 Pandemic
A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 Vaccine
This study is a randomized, double-blind, placebo-controlled Phase II clinical trial to evaluate the safety and immunogenicity of SCTV01E in population of different ages who have been vaccinated against COVID-19.
- Trial name
- SCTV01E (NCT05652543)
- Testing
- SCTV01E
- Where
- 4 sites in China
- Volunteers
- 518 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
SARS-CoV-2 Infection, COVID-19
A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
The purpose of this clinical protocol is to learn about the safety, tolerability, and immunogenicity of new BNT162b2 RNA-based vaccine candidates targeting new variants of SARS-CoV-2 in healthy people.
- Trial name
- NCT05997290
- Testing
- BNT162b2 (Omi XBB.1.5), BNT162b2 (Omi JN.1), BNT162b2 (Omi KP.2)
- Where
- 37 sites in United States
- Volunteers
- 1,051 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Healthy
Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]-PF-07304814 in Healthy Participants
This open-label, single dose study in approximately 5 healthy male and female (of non childbearing potential only) participants has been designed to characterize mass balance and further the understanding of human…
- Trial name
- NCT05050682
- Testing
- PF-07304814
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19
Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease
This study evaluates the efficacy and safety of intravenous (IV) infusions of pamrevlumab when compared with placebo in participants who are hospitalized with acute COVID-19 disease.
- Trial name
- NCT04432298
- Testing
- Pamrevlumab
- Where
- 4 sites in United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Kyntra Bio
COVID-19, SARS-CoV-2 Acute Respiratory Disease
Assessing the Immunogenicity and Safety of a HIPRA's Candidate Booster Vaccination in Adults Fully Vaccinated With Adenovirus Vaccine Against COVID-19.
Phase IIb clinical trial to assess the Immunogenicity and Safety of a HIPRA's Candidate Booster vaccination (PHH-1V) in adults fully vaccinated with the adenovirus vaccine Vaxevria against COVID-19.
- Trial name
- NCT05305573
- Testing
- COVID-19 Vaccine HIPRA 40 ug/dose, Comirnaty (Pfizer-BioNtech) 30 ug/dose concentrate for dispersion for injection
- Where
- 7 sites in Spain
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Hipra Scientific, S.L.U
Covid19
Evaluation of a COVID-19 Pneumonia CXR AI Detection Algorithm
This study investigates the diagnostic performance of an AI algorithm in the detection of COVID-19 pneumonia on chest radiographs.
- Trial name
- NCT04561024
- Testing
- AI model
- Where
- Hong Kong
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Ensemble Group Holdings, LLC
COVID-19
Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant
2019nCoV-101 is a 2-part, randomized, observer-blinded, placebo-controlled, Phase 1/2 trial. Part 1 (Phase 1) of the study is designed to evaluate the safety and immunogenicity of SARS-CoV-2 rS nanoparticle vaccine with or…
- Trial name
- NCT04368988
- Testing
- SARS-CoV-2 rS - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1
- Where
- 18 sites in United States, Australia
- Volunteers
- 1,419 people, healthy volunteers welcome
- Sponsor
- Novavax
COVID-19
IH Convidecia as Second Booster Dose Against Breakthrough Infections
This will be a randomized single-blind controlled trial to determine the immunogenicity, efficacy and safety of IH Convidecia (CanSino), as a second booster vaccination against Omicron and other emerging VOCs to prevent…
- Trial name
- NCT05517642
- Testing
- Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH), mRNA vaccine BNT162b2 (Pfizer)
- Where
- Malaysia
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Covid-19, SARS-CoV-2
A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine
This is a Phase 2/3, randomized, multicenter, double-blind, dose-response study to evaluate the safety, immunogenicity, and efficacy of UB 612 in 2 age groups, adults 18 to 59 and ≥60 years of age with or without comorbidities.
- Conditions
- Covid-19, SARS-CoV-2, Coronavirus
- Trial name
- NCT04683224
- Testing
- UB-612
- Volunteers
- healthy volunteers welcome
- Sponsor
- Vaxxinity, Inc.
Healthy Volunteers
Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)
A study to evaluate the immune response and safety of AdCOVID administered as an intranasal spray in healthy adults.
- Trial name
- NCT04679909
- Testing
- AdCOVID
- Where
- 6 sites in United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Altimmune, Inc.
SARS-CoV-2 Infection
To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P63 in Healthy Subjects
This is a Phase I study that randomized, double-blind, Placebo-controlled, Parallel Group, Single Ascending Dose Study to evaluate Safety, Tolerability and Pharmacokinetics of CT-P63 in Healthy Subjects.
- Trial name
- NCT05017168
- Testing
- CT-P63
- Where
- Poland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Celltrion
COVID-19
Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19
The purpose of this double-blind, randomized, controlled study is to assess immunogenicity and safety of 202-CoV at multiple dose levels, administered as 2 injections (i.m) at 28 days apart in adult subjects 18 years of age and…
- Trial name
- NCT04990544
- Testing
- 202-CoV low adjuvant dose, 202-CoV low antigen dose, 202-CoV standard dose
- Where
- China
- Volunteers
- 528 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
SARS-CoV-2 Infection
A Phase 1 Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine
A randomised, blinded, parallel-controlled phase 1 clinical trial to evaluate the safety and preliminary immunogenicity of a COVID-19 mRNA vaccine in a healthy population aged 18 years and older, and to investigate immunisation…
- Trial name
- NCT06113744
- Testing
- COVID-19 Vaccine (Vero Cell) ,Inactivated, COVID-19 mRNA Vaccine (ZSVG-02-O) 10 μg, COVID-19 mRNA Vaccine (ZSVG-02-O) 30 μg
- Where
- China
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- CNBG-Virogin Biotech (Shanghai) Ltd.
COVID-19
Study of COVID-19 DNA Vaccine (AG0302-COVID19)
This study will assess the safety and immunogenicity of AG0302-COVID19 in healthy adult volunteers.
- Trial name
- NCT04527081
- Testing
- AG0302-COVID19
- Where
- Japan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AnGes, Inc.
Covid19, SARS CoV 2 Infection
Safety and Immunogenicity Study of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers (COVID-19)
This is a first-in-human, phase I/IIa, randomized, controlled, observer-blinded, dose-escalation, multicentre clinical trial to evaluate safety and immunogenicity of COVID-19 HIPRA vaccine in adult healthy volunteers.
- Trial name
- NCT05007509
- Testing
- COVID-19 vaccine HIPRA 10, COVID-19 vaccine HIPRA 20, COVID-19 vaccine HIPRA 40
- Where
- 2 sites in Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Laboratorios Hipra, S.A.